Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Last I knew V was out of formulary

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Chemist2 Member Profile
 
Followed By 7
Posts 433
Boards Moderated 0
Alias Born 08/27/17
160x600 placeholder
Amarin Files Patent Infringement Lawsuit Against Hikma GlobeNewswire Inc. - 11/30/2020 7:54:44 PM
Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) GlobeNewswire Inc. - 11/24/2020 6:05:00 AM
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China GlobeNewswire Inc. - 11/19/2020 6:30:00 PM
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association’s Virtual Scie... GlobeNewswire Inc. - 11/18/2020 7:00:00 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Graft... GlobeNewswire Inc. - 11/13/2020 10:00:00 AM
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences GlobeNewswire Inc. - 11/11/2020 4:30:00 PM
Epazz, Inc. (OTC Pink: EPAZ) and Zoom (NASDAQ: ZM) for a Covid-19 Surge InvestorsHub NewsWire - 11/9/2020 6:00:00 AM
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/5/2020 6:00:00 AM
New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scienti... GlobeNewswire Inc. - 10/29/2020 7:00:10 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function a... GlobeNewswire Inc. - 10/26/2020 7:00:10 AM
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderat... GlobeNewswire Inc. - 10/23/2020 7:00:10 AM
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 GlobeNewswire Inc. - 10/19/2020 7:00:10 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interv... GlobeNewswire Inc. - 10/15/2020 4:30:10 PM
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EA... GlobeNewswire Inc. - 10/5/2020 7:00:10 AM
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/9/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:21:33 PM
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation GlobeNewswire Inc. - 9/3/2020 10:51:52 AM
Traders News Source Issues "Potential Home Run" New Research Report InvestorsHub NewsWire - 9/3/2020 9:00:00 AM
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Ri... GlobeNewswire Inc. - 9/1/2020 4:30:10 PM
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ES... GlobeNewswire Inc. - 8/29/2020 3:13:10 AM
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented... GlobeNewswire Inc. - 8/17/2020 7:00:10 AM
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Chemist2   Tuesday, 09/17/19 12:52:14 AM
Re: Mellowmood77 post# 214659
Post # of 312535 
Last I knew V was out of formulary with my Kaiser in MD; persuaded my Dr.
to prescribe but I get it at CVS and pay 100%, ~$200/month after coupon.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences